Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

15.61EUR
15 Aug 2018
Change (% chg)

€0.62 (+4.14%)
Prev Close
€14.99
Open
€15.02
Day's High
€15.91
Day's Low
€15.02
Volume
539,339
Avg. Vol
399,778
52-wk High
€15.94
52-wk Low
€7.28

Latest Key Developments (Source: Significant Developments)

Almirall H1 Net Result Turns To Profit Of 52 Mln Euros YoY
Monday, 30 Jul 2018 

July 30 (Reuters) - Almirall SA ::H1 NET PROFIT 52.0 MILLION EUROS VERSUS LOSS 73.1 MILLION EUROS YEAR AGO.H1 EBITDA 105.5 MILLION EUROS VERSUS 58.6 MILLION EUROS YEAR AGO.H1 REVENUE 398.3 MILLION EUROS VERSUS 378.9 MILLION EUROS YEAR AGO.UPGRADES 2018 EBITDA GUIDANCE, NOW SEES YOY GROWTH C. 30% VERSUS ORIGINAL EBITDA FORECAST OF C. 20% GROWTH.CONFIRMS TOTAL REVENUE GUIDANCE FOR 2018.SEES DECLINE IN SALES AT THERMIGEN, DUE TO EARLY TERMINATION OF INSTALIFTTM AGREEMENT AND POOR PERFORMANCE OF CAPITAL SALES.  Full Article

Almirall: Both Phase III Trials Of KX2-391 For Actinic Keratosis Achieve Primary Endpoint
Thursday, 26 Jul 2018 

July 26 (Reuters) - Almirall SA ::ANNOUNCES THAT BOTH PHASE III TRIALS OF KX2- 391 FOR ACTINIC KERATOSIS ACHIEVED PRIMARY ENDPOINT.  Full Article

Almirall: Phase III Trial Of P3074 Positive, Phase II Review Of PAT001 Didn't Meet Criteria
Monday, 25 Jun 2018 

June 25 (Reuters) - Almirall SA ::SAYS TOP-LINE RESULTS OF PHASE III TRIAL OF P3074 (ANDROGENETIC ALOPECIA) WERE POSITIVE.SAYS PHASE II REVIEW OF PAT001 (ICHTHYOSIS) DID NOT MEET ALMIRALL’S INTERNAL DEVELOPMENT CRITERIA.SAYS REST OF CO’S RESEARCH AND DEVELOPMENT PIPELINE IS PROGRESSING AS EXPECTED.  Full Article

Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain
Friday, 22 Dec 2017 

Dec 22 (Reuters) - ALMIRALL SA ::EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN).LICENSE AGREEMENT GRANTS ALMIRALL EXCLUSIVE RIGHTS TO COMMERCIALIZE CRESTOR AND PROVISACOR IN SPAIN.  Full Article

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALMIRALL SA ::ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​.TUDORZA REDUCES CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND DEMONSTRATES CARDIOVASCULAR SAFETY.‍​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Almirall says Tildrakizumab launch in Europe moved to end-2018 or early 2019‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ALMIRALL SA ::SAYS ANTICIPATED APPROVAL FOR TILDRAKIZUMAB AND ITS LAUNCH IN EUROPE ARE MOVED FROM MID-2018 TO END OF 2018 OR EARLY 2019.‍​.  Full Article

Almirall 9-month net result turns to loss of 99.7 mln euros YoY
Monday, 6 Nov 2017 

Nov 6 (Reuters) - ALMIRALL SA ::9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO.9-MONTH REVENUE 561.6 MILLION EUROS VERSUS 635.4 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 99.7 MILLION EUROS VERSUS PROFIT 103.5 MILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT EXPENSES 67.2 MILLION EUROS VERSUS 61.8 MILLION EUROS YEAR AGO.REITERATES ESTIMATES ANNOUNCED ON JULY 10.  Full Article

Almirall ends phase III research for nail psoriasis product in Europe
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - ALMIRALL SA ::TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT.  Full Article

Spain's Almirall bets on dermatology with $650 million U.S. deal

Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.